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Abstract: Artemisinin and synthetic derivatives of dihydroartemisinin are known to possess
various biological activities. Post-functionalization of dihydroartemisinin with triazole heterocycles
has been proven to lead to enhanced therapeutic potential. By using our newly developed
triazolization strategy, a library of unexplored fused and 1,5-disubstituted 1,2,3-triazole derivatives
of dihydroartemisinin were synthesized in a single step. All these newly synthesized compounds
were characterized and evaluated for their anti-HIV (Human Immunodeficiency Virus) potential in
MT-4 cells. Interestingly; three of the synthesized triazole derivatives of dihydroartemisinin showed
activities with half maximal inhibitory concentration (IC50) values ranging from 1.34 to 2.65 µM.
Keywords: triazole; artemisinin; triazolization; organocatalytic; multicomponent reaction
1. Introduction
The human immunodeficiency virus (HIV), the causative agent of the acquired immunodeficiency
syndrome (AIDS), has been plaguing the human race for more than thirty years [1]. According to the
global statistics of UNAIDS, it has been estimated that globally 36.7 million people were suffering
from HIV/AIDS in 2015 [2]. Even though more than thirty drugs targeting different steps of the
viral life cycle are either approved or in clinical stages to treat HIV/AIDS [2], a cure remains elusive.
Moreover, emergence of HIV strains that are no longer sensitive to the drug cocktails employed is
leading to inability to completely block the viral replication [3]. Thus, finding new anti-HIV agents that
are less toxic and more effective in targeting HIV reservoirs in the body is still needed. Artemisinin,
a naturally occurring 1,2,4-trioxane sesquiterpene, first isolated in 1972 from a Chinese medicinal plant
(Artemisia annua L.) that had been used as a treatment for fever for many centuries [4]. Interestingly,
artemisinin has been used successfully at nanomolar concentrations against both chloroquine-sensitive
and -resistant strains of Plasmodium falciparum. However, its therapeutic efficiency is not optimal due
to poor oral bioavailability and limited solubility [5,6]. Reduction of the carbonyl group of artemisinin
leads to the synthesis of dihydroartemisinin in high yields without disrupting the unusual peroxide
linkage of artemisinin which has in turn lead to the development of a series of semi-synthetic first
generation derivatives including the oil soluble artemether and arteether, and water soluble sodium
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Dihydroartemisinin has become a subject of considerable interest in medicinal chemistry for
its therapeutic value, better solubility, and being a versatile precursor for the synthesis of wide
variety of other artemisinin derivatives [4]. Furthermore, derivatives of dihydroartemisinin are
found to have antiproliferative, antibacterial, antiviral, and immunosuppressive activities [8–21].
Even though it displays a high activity profile, dihydroartemisinin does suffer some drawbacks
such as neurotoxicity in animal models, short pharmacological half-life, and recrudescence of the
disease [22,23]. The shortcomings of the current artemisinin derivatives and emergence of multidrug
resistance for artemisinin based combination therapies [24] are the motivation to search for novel
artemisinin compounds.
Although 1,2,3-triazole derivatives of artemisinin have been synthesized and evaluated for
biological activity [25,26], no attempt has been made to synthesize 1,5-disubstituted 1,2,3-triazole
derivatives of dihydroartemisinin in a single step and metal-free conditions. The widespread
applications of 1,2,3-triazoles have triggered the demand for metal free and easier access to this
privileged scaffold. Herein we disclose the implementation of our recently developed triazolization
strategy [27–29] in which dihydroartemisinin scaffold was joined with variety of interesting heterocyclic
moieties. We presume that this strategy could help in synthesizing a series of compound with minimal
effort to obtain various fused and 1,5-disubstituted triazole derivatives of dihydroartemisinin.
2. Results and Discussion
2.1. Organocatalytic Synthesis of Triazole Functionalized Artemisinin
As an effective ethod of functionalizing dihydroarte isinin ith triazole heterocycle, e
i ple ented our recently developed triazolization strategy [27–29]. The ethod generally involves
the reaction of a pri ary a ine and an enolizable ketone 6 in the presence of 4-nitrophenyl azide 7
as a source of dinitrogen. The echanistic study of this reaction indicated that an equilibriu exists
bet een i ine and ena ine follo ed by an ena ine ediated [3+2] cycloaddition reaction. This
leads to the for ation of a triazole inter ediate followed by eli ination of nitroaniline which gave
the fused or 1,5-disubstituted 1,2,3-triazole derivative of dihydroarte isinin.
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Initially, the amine functionalized dihydroartemisinin 5 was synthesized by a
previously reported procedure [30]. It involves the conversion of dihydroartemisinin into
10-bromoethoxydihydroartemisinin (2) by using 2-bromoethanol (3) in the presence of BF3·Et2O
as a catalyst. Reaction of sodium azide with 10-bromoethoxydihydroartemisinin (2) afforded
2-(10β-dihydroartemisinoxy) ethyl azide (4) in 95% isolated yield (Scheme 1). The azido compound
was then reduced to 2-(10β-dihydroartemisinoxy) ethyl amine (5) in 74% yield via a Staudinger
reduction (Scheme 1).Molecules 2017, 22, 303 3 of 12 
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Scheme 1. Synthetic route towards the preparation of amine precursor 4. DCM: dichloromethane;
DMF: dimethylformamide; THF: tetrahydrofuran.
The amine-modified di ydroa temisinin was then tested for the triazolization strategy with
various aromatic and enolizable ketones. Cyclic ketones such as tetralones and their derivatives reacted
smoothly under the modified triazolization conditions leading to the expected product in moderate
yield. Acetophenone was also converted to the desired product 8f (Table 1). Next, the versatility of
this triazolization reaction was shown by functionalizing the modified dihydroartemisinin 5 with the
male sex hormone analogue dihydrotestosterone and the triterpene betulonic acid giving rise to the
fused triazole derivatives 8k and 8l, respectively, in moderate yield shown in Table 1.
In the next series of experiments, w reverse the strategy by functionalizing dihydroartemisinin
scaffold with symmetrical enolizable cycli ketone. The buil ing block 9 was ob ain d by
classic l DCC (N,N’-dicyclohexylcarbodiimide) coupling reaction f dihydroartemisinin with
cyclohexanone-4-carboxylic acid isolated in 82% yield (Scheme 2).
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Table 1. Substrate scope with respect to ketones a.
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The versatility of our triazolization methodology was further exploited by condensing
with various commercial and biologically relevant primary amine derivatives. Ketone-modified
dihydroartemisinin 9 was treated with various benzylamines which led to the synthesis of triazole
conjugate in good yield (Table 2). Tryptamine also works fine under these reaction circumstances
leading to the expected product 11d in moderate yield (Table 2).
Molecules 2017, 22, 303 5 of 13
Table 2. Substrate scope with respect to amines a.
Molecules 2017, 22, 303 5 of 12 
 
Table 2. Substrate scope with respect to amines a. 
 
a Reagents and conditions: 9 (1.0 equiv.), 10 (1.0 equiv.), 7 (1.2 equiv.), toluene (0.4 mL), 60 °C, 16 h, isolated yield. 
2.2. Anti-Human Immunodeficiency Virus Activity Evaluation 
The newly synthesized dihydroartemisinin triazole derivatives were evaluated for their inhibitory 
effects (IC50) on the replication of wild-type HIV-1 (IIIB) and HIV-2 (ROD) in MT-4 cell cultures, in 
parallel with their cytotoxicities (CC50) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) method [31]. A series of nucleoside reverse transcriptase inhibitors (NRTIs)— 
i.e., azidothymidine (AZT), lamivudine (3TC) and didanosine (DDI)—and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs)—i.e., nevirapine (NVP), efavirenz (EFV), and etravirine (ETR)—
were included as reference compounds. The biological results are represented as IC50 and CC50 values 
in Table 3. 
Most of the new triazole analogues of dihydroartemisinin are completely devoid of anti-HIV 
activity. However, the unsubstituted β-2-tetralone analogue 8b exhibited moderate activity against 
wild-type (wt) HIV-1 IIIB with IC50 value of 2.78 µM, whereas its α-tetralone analogue 8a did not show 
any activity. Both the mono and di-methoxy β-tetralone analogues 8e and 8c, are slightly less active 
against HIV-1 wt IC50 values of 5.18 and 4.06 µM respectively. The active molecules were also evaluated 
for their inhibitory activity against a double reverse transcriptase mutant (K103N; Y181C) HIV-1 strain 
(RES056). The derivatives 8b, 8c and 8e, just like the first generation NNRTI nevirapine, completely 
lose their inhibitory activity, whereas the anti-HIV activity of efavirenz and etravirine is only slightly 
affected. Therefore, the active β-tetralone derivatives most probably act via an NNRTI-type mode  
of action. 
  
2.2. Anti-Human Immunodeficiency Virus Activity Evaluation
The newly synthesized dihydroartemisinin triazole derivatives were evaluated for their inhibitory
effects (IC50) on the replication of wild-type HIV-1 (IIIB) and HIV-2 (ROD) in MT-4 cell cultures,
in parallel with their cytotoxicities (CC50) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) method [31]. A series of nucleoside reverse transcriptase inhibitors
(NRTIs)—i.e., azidothymidine (AZT), lamivudine (3TC) and didanosine (DDI)—and non-nucleoside
reverse transcriptase inhibitors (NNRTIs)—i.e., nevirapine (NVP), efavirenz (EFV), and etravirine
(ETR)—were included as reference compounds. The biological results are represented as IC50 and
CC50 values in Table 3.
Most of the new triazole analogues of dihydroartemisinin are completely devoid of anti-HIV
activity. However, the unsubstituted β-2-tetralone analogue 8b exhibited moderate activity against
wild-type (wt) HIV-1 IIIB with IC50 value of 2.78 µM, whereas its α-tetralone analogue 8a did not
show any activity. Both the mono and di-methoxy β-tetralone analogues 8e and 8c, are slightly less
active against HIV-1 wt IC50 values of 5.18 and 4.06 µM respectively. The active molecules were
also evaluated for their inhibitory activity against a double reverse transcriptase mutant (K103N;
Y181C) HIV-1 strain (RES056). The derivatives 8b, 8c and 8e, just like the first generation NNRTI
nevirapine, completely lose their inhibitory activity, whereas the anti-HIV activity of efavirenz and
etravirine is only slightly affected. Therefore, the active β-tetralone derivatives most probably act via
an NNRTI-type mode of action.
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Table 3. In vitro anti-HIV activity and cytotoxicity of triazole derivatives of dihydroartemisinin.
Compound
IC50 (µM) a
CC50 (µM) b
HIV-1 Strain IIIB HIV-2 Strain ROD HIV-1 Strain RES056
8a >10.3 >10.3 NT c >10.3
8b 2.78 >31.5 >31.5 31.5
8c 4.06 >21.2 >21.2 21.2
8e 5.18 >14.9 >14.9 14.9
Azidothymidine 0.0064 0.0082 0.0071 >7.50
Lamivudine 2.53 9.90 NT >87.2
Didanosine 76.0 82.1 NT >212
Nevirapine 0.075 >15.0 >15.0 >15.0
Efavirenz 0.0024 >6.3 0.18 >6.3
Etravirine 0.0034 >2.29 0.045 2.29
a IC50: concentration of compound required to achieve 50% protection of MT-4 cell cultures against HIV-1-induced
cytotoxicity, as determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method;
b CC50: concentration required to reduce the viability of mock-infected cell cultures by 50%, as determined by the
MTT method; c Not tested.
3. Experimental Section
3.1. General Information
1H- and 13C-NMR spectra were recorded on commercial instruments (Bruker AMX 400 MHz or
Bruker Avance II+ 600 MHz, Bruker, Rheinstetten, Germany) and chemical shifts (δ) are referenced
to tetramethylsilane (1H), or the internal (NMR) solvent signal (13C). For column chromatography
70–230 mesh silica 60 (E. M. Merck, Steinheim am Albuch, Germany) was used as the stationary phase.
Chemicals received from commercial sources were used without further purification. Synthesis of
5 was carried out based on the literature report and exactly matched with reported NMR data [30].
Other products’ NMR spectra see Supplementary Materials.
3.2. General Procedure for Modified Triazolization Reaction
A flame-dried screw-capped reaction tube equipped with magnetic stirring bar was charged with
amine, ketone, 4-nitrophenylazide, and 4 Å molecular sieves. The mixture was dissolved in toluene
(0.4 mL) and stirred at 60 ◦C for 18–36 h. The reaction was monitored by Thin-layer chromatography
and after completion of reaction, the solvent was removed in vacuo. The crude reaction mixture was
then subsequently purified by column chromatography (silica gel) first using DCM (dichloromethane)
as eluent to remove all 4-nitroaniline formed during the reaction, followed by a mixture of heptane
and ethyl acetate as the eluent to afford the title product.
3.3. Characterization of the Products
1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-
yl)oxy)ethyl)-4,5-dihydro-1H-naphtho[1,2-d][1,2,3]triazole (8a): 5 (60 mg, 0.183 mmol), α-tetralone
(26.8 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol). Reaction time was 24 h.
The product was purified by flash column chromatography (first DCM, followed by
EtOAc/heptane = 3:2) to afford 8a (42 mg, 48%) as an off-white semisolid: 1H-NMR (400 MHz, CDCl3)
δ 7.94 (d, J = 7.4 Hz, 1H), 7.30 (td, J = 7.4, 1.8 Hz, 1H), 7.24–7.17 (m, 2H), 5.38 (s, 1H), 4.62 (d, J = 8.0 Hz,
1H), 4.60–4.54 (m, 1H), 4.53–4.44 (m, 1H), 4.23 (dt, J = 10.6, 4.3 Hz, 1H), 3.91 (ddd, J = 10.7, 8.6, 4.0 Hz,
1H), 3.09–2.91 (m, 4H), 1.87–1.81 (m, 1H), 1.71–1.62 (m, 3H), 1.60–1.49 (m, 3H), 1.47 (s, 3H), 1.44–1.35
(m, 1H), 1.29 (dt, J = 14.4, 3.2 Hz, 1H), 1.22–1.09 (m, 2H), 1.06–0.95 (m, 1H), 0.88 (dd, J = 6.3, 3.6 Hz,
6H). 13C-NMR (101 MHz, CDCl3) δ 143.34, 134.03, 133.69, 129.04, 128.19, 127.37, 127.35, 122.16, 107.27,
101.43, 97.25, 82.73, 68.54, 48.50, 45.24, 44.11, 39.98, 35.27, 34.55, 34.52, 32.81, 28.81, 23.87, 22.17, 19.41,
19.34, 18.76.
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3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-
yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole (8b): 5 (60 mg, 0.183 mmol), β-tetralone
(26.8 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol). Reaction time was 16 h. The product
was purified by flash column chromatography (first DCM, then EtOAc/heptane = 3:2) to afford 8b
(62 mg, 70%) as an off-white solid: m.p. 104–105 ◦C; 1H-NMR (400 MHz, CDCl3) δ 7.94 (d, J = 7.4 Hz,
1H), 7.30 (td, J = 7.4, 1.8 Hz, 1H), 7.24–7.17 (m, 2H), 5.38 (s, 1H), 4.62 (d, J = 8.0 Hz, 1H), 4.60–4.54
(m, 1H), 4.53–4.44 (m, 1H), 4.23 (dt, J = 10.6, 4.3 Hz, 1H), 3.91 (ddd, J = 10.7, 8.6, 4.0 Hz, 1H), 3.09–2.91
(m, 4H), 1.87–1.81 (m, 1H), 1.71–1.62 (m, 3H), 1.60–1.49 (m, 3H), 1.47 (s, 3H), 1.44–1.35 (m, 1H), 1.29
(dt, J = 14.4, 3.2 Hz, 1H), 1.22–1.09 (m, 2H), 1.06–0.95 (m, 1H), 0.88 (dd, J = 6.3, 3.6 Hz, 6H). 13C-NMR
(101 MHz, CDCl3) δ 143.34, 134.03, 133.69, 129.04, 128.19, 127.37, 127.35, 122.16, 107.27, 101.43, 97.25,
82.73, 68.54, 48.50, 45.24, 44.11, 39.98, 35.27, 34.55, 34.52, 32.81, 28.81, 23.87, 22.17, 19.41, 19.34, 18.76.
7,8-Dimethoxy-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]
isochromen-10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole (8c): 5 (60 mg, 0.183 mmol),
6,7-dimethoxy-3,4-dihydronaphthalen-2(1H)-one (37.8 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 16 h. The product was purified by flash column chromatography
(first DCM, followed by EtOAc/heptane = 3:2) to give 8c (67 mg, 67%) as an off-white semisolid:
1H-NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 6.76 (s, 1H), 5.38 (s, 1H), 4.62 (d, J = 7.9 Hz, 1H), 4.59–4.53
(m, 1H), 4.51–4.44 (m, 1H), 4.26–4.18 (m, 1H), 3.95 (s, 3H), 3.89 (s, 4H), 3.05–2.84 (m, 4H), 1.88–1.79
(m, 1H), 1.71–1.62 (m, 3H), 1.60–1.50 (m, 3H), 1.47 (s, 3H), 1.44–1.35 (m, 1H), 1.33–1.23 (m, 2H),
1.21–1.10 (m, 1H), 1.08–0.95 (m, 1H), 0.91–0.85 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 148.40, 148.20,
143.46, 133.09, 125.92, 121.85, 111.89, 107.25, 105.67, 101.41, 97.24, 82.71, 68.50, 56.26, 56.18, 48.52, 45.23,
44.12, 39.97, 35.26, 34.55, 34.51, 32.80, 28.45, 23.85, 22.16, 19.62, 19.32, 18.74.
8-Nitro-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-
10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole (8d): 5 (60 mg, 0.183 mmol), 7-nitro-3,
4-dihydronaphthalen-2(1H)-one (35 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol).
Reaction time was 16 h. Flash column chromatography (first DCM, followed by EtOAc/heptane = 3:2)
afforded 8d (70.4 mg, 73%) as an off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 8.78 (d, J = 2.2 Hz,
1H), 8.12 (dd, J = 8.3, 2.3 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 5.38 (s, 1H), 4.91–4.87 (m, 2H), 4.61
(d, J = 7.9 Hz, 1H), 4.45–4.39 (m, 1H), 4.15–4.01 (m, 1H), 3.15–3.02 (m, 4H), 1.86–1.79 (m, 1H), 1.69–1.61
(m, 3H), 1.55–1.48 (m, 3H), 1.44 (s, 3H), 1.36–1.32 (m, 1H), 1.32–1.27 (m, 2H), 1.21–1.11 (m, 1H),
1.02–0.92 (m, 1H), 0.88–0.76 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 147.43, 145.81, 144.66, 131.02,
129.79, 126.95, 123.16, 118.31, 107.19, 101.28, 97.24, 82.76, 77.16, 68.37, 50.36, 45.28, 44.08, 39.56, 35.21,
34.58, 34.51, 32.61, 30.78, 29.85, 23.85, 22.17, 20.38, 19.18, 18.80.
8-Methoxy-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]
isochromen-10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole (8e): 5 (60 mg, 0.183 mmol),
7-methoxy-3,4-dihydronaphthalen-2(1H)-one (32.3 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 16 h. The product was purified by flash column chromatography
(first DCM, followed by EtOAc/heptane = 3:2) to afford 8e (62 mg, 66%) as an off-white semisolid:
1H-NMR (400 MHz, CDCl3) δ 7.51 (d, J = 2.7 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.75 (dd, J = 8.3,
2.7 Hz, 1H), 5.37 (s, 1H), 4.62 (d, J = 8.0 Hz, 1H), 4.60–4.54 (m, 1H), 4.53–4.45 (m, 1H), 4.27–4.19 (m,
1H), 3.95–3.88 (m, 1H), 3.86 (s, 3H), 3.04–2.88 (m, 4H), 1.86–1.80 (m, 1H), 1.71–1.62 (m, 3H), 1.61–1.49
(m, 3H), 1.47 (s, 3H), 1.43–1.35 (m, 1H), 1.34–1.27 (m, 2H), 1.22–1.15 (m, 1H), 1.06–0.95 (m, 1H),
0.90–0.86 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 159.10, 143.39, 134.39, 129.97, 129.15, 125.68, 113.95,
107.26, 106.62, 101.41, 97.23, 82.71, 68.49, 55.62, 48.52, 45.22, 44.10, 39.95, 35.25, 34.54, 34.50, 32.79, 27.96,
23.85, 22.15, 19.63, 19.32, 18.74.
5-Phenyl-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]
isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (8f): 5 (60 mg, 0.183 mmol), acetophenone (22 mg,
0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol). Reaction time was 24 h. The product was
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purified by flash column chromatography (at first DCM followed by EtOAc/heptane = 3:2) to give 8f
(41 mg, 49%) as an off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.53–7.44 (m, 5H),
5.35 (s, 1H), 4.64–4.46 (m, 3H), 4.32–4.21 (m, 1H), 4.12–4.00 (m, 1H), 1.88–1.79 (m, 1H), 1.70–1.62 (m,
3H), 1.61–1.49 (m, 3H), 1.47 (s, 3H), 1.42–1.33 (m, 1H), 1.31–1.22 (m, 2H), 1.21–1.12 (m, 1H), 1.06–0.94
(m, 1H), 0.89–0.81 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 138.90, 132.92, 129.45, 129.26, 129.10, 127.25,
107.23, 101.60, 97.23, 82.71, 68.08, 48.04, 45.27, 44.12, 39.70, 35.27, 34.57, 34.53, 32.79, 23.86, 22.17,
19.19, 18.76.
5-(3,4-Dibromophenyl)-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]
dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (8g): 5 (60 mg, 0.183 mmol),
1-(3,4-dibromophenyl)ethan-1-one (51 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 36 h. Flash column chromatography purification (DCM first,
followed by EtOAc/heptane = 3:2) afforded 8g (42 mg, 37%) as an off-white solid: m.p. 105–106 ◦C;
1H-NMR (400 MHz, CDCl3) δ 7.83 (d, J = 2.0 Hz, 1H), 7.73–7.69 (m, 2H), 7.32 (dd, J = 8.3, 2.1 Hz, 1H),
5.31 (s, 1H), 4.60–4.52 (m, 3H), 4.28–4.22 (m, 1H), 4.07–4.00 (m, 1H), 1.86–1.80 (m, 1H), 1.71–1.64 (m,
2H), 1.62–1.56 (m, 3H), 1.54–1.49 (m, 1H), 1.46 (s, 3H), 1.32–1.22 (m, 3H), 1.19–1.10 (m, 2H), 1.04–0.95
(m, 1H), 0.88 (d, J = 5.7 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H). 13C-NMR (151 MHz, CDCl3) δ 134.32, 134.22,
133.20, 129.19, 128.04, 126.35, 125.68, 107.26, 101.58, 97.21, 82.71, 68.42, 48.52, 45.24, 44.09, 39.71, 35.27,
34.56, 34.53, 32.81, 23.87, 22.17, 19.22, 18.78.
5-(Naphthalen-1-yl)-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]
dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (8h): 5 (60 mg, 0.183 mmol),
1-(naphthalen-1-yl)ethan-1-one (31.2 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 36 h. The product was purified by flash column chromatography
(first DCM, then EtOAc/heptane = 3:2) to afford 8h (49 mg, 53%) as an off-white semisolid: 1H-NMR
(400 MHz, CDCl3) δ 7.97 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 7.58–7.46 (m, 5H),
5.24 (s, 1H), 4.51 (d, J = 8.0 Hz, 1H), 4.42–4.34 (m, 2H), 4.13–4.04 (m, 1H), 3.92–3.83 (m, 1H), 1.84–1.78
(m, 1H), 1.72–1.58 (m, 3H), 1.57–1.45 (m, 3H), 1.41 (s, 3H), 1.31–1.23 (m, 1H), 1.19–1.09 (m, 3H),
1.01–0.93 (m, 1H), 0.89–0.80 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 136.53, 134.52, 133.76, 132.25,
130.29, 129.05, 128.66, 127.34, 126.66, 125.27, 125.00, 124.59, 107.13, 101.35, 97.16, 82.65, 67.70, 48.24,
45.26, 44.05, 39.52, 35.23, 34.56, 34.52, 32.70, 23.83, 22.15, 19.25, 18.76.
2-Methoxy-4-(1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]
dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazol-5-yl)phenol (8i): 5 (60 mg, 0.183 mmol),
1-(4-hydroxy-3-methoxyphenyl)ethan-1-one (30.5 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 36 h. The product was purified by flash column chromatography
(first DCM, followed by EtOAc/heptane = 3:2) to give 8i (35 mg, 38%) as an off-white semisolid:
1H-NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.01 (s, 3H), 5.86 (s, 1H), 5.34 (s, 1H), 4.59 (d, J = 7.9 Hz, 1H),
4.57–4.44 (m, 2H), 4.31–4.21 (m, 1H), 4.11–4.02 (m, 1H), 3.93 (s, 3H), 1.88–1.80 (m, 1H), 1.70–1.58 (m,
3H), 1.57–1.50 (m, 3H), 1.47 (s, 3H), 1.40–1.31 (m, 1H), 1.30–1.20 (m, 2H), 1.18–1.10 (m, 1H), 1.06–0.96
(m, 1H), 0.89–0.81 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 146.91, 138.98, 132.62, 122.83, 118.92, 115.07,
111.85, 107.27, 101.57, 97.25, 82.69, 68.20, 56.29, 47.85, 45.25, 44.10, 39.83, 35.27, 34.56, 34.53, 32.81, 29.84,
23.84, 22.17, 19.19, 18.77.
5-Benzyl-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]
dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine (8j): 5
(60 mg, 0.183 mmol), 1-benzylpiperidin-4-one (34.7 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg,
0.220 mmol). Reaction time was 16 h. The product was purified by flash column chromatography (first
DCM, next EtOAc/heptane = 3:2) to afford 8j (61 mg, 63%) as an off-white semisolid: 1H-NMR (400
MHz, CDCl3) δ 7.38–7.28 (m, 5H), 5.37 (s, 1H), 4.60 (d, J = 7.9 Hz, 1H), 4.52–4,46 (m, 1H), 4.42–4.34
(m, 1H), 4.23–4.17 (m, 1H), 3.90–3.82 (m, 1H), 3.75 (s, 2H), 3.72–3.64 (m, 2H), 2.85–2.68 (m, 4H),
1.85–1.81 (m, 1H), 1.70–1.53 (m, 6H), 1.47 (s, 3H), 1.39–1.36 (m, 1H), 1.34–1.26 (m, 1H), 1.95–1.12
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(m, 2H), 1.08–0.99 (m, 1H), 0.92–0.83 (m, 6H). 13C-NMR (101 MHz, CDCl3) δ 142.03, 138.18, 131.76,
129.08, 128.52, 127.46, 107.26, 101.43, 97.23, 82.71, 68.54, 61.64, 49.92, 49.39, 48.23, 45.25, 44.14, 39.93,
35.26, 34.55, 34.52, 32.81, 29.82, 23.86, 22.16, 20.99, 19.28, 18.76.
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-Dimethyl-7-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-
decahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-1,2,3,3a,3b,4,5,5a,6,7,10,10a,
10b,11,12,12a-hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-1-ol (8k): 5 (60 mg, 0.183 mmol),
(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-
3-one (53.2 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol). Reaction time was 16 h. Flash
column chromatography (first DCM, followed by EtOAc/heptane = 3:2) yielded 8k (72 mg, 63%) as an
off-white solid: m.p. 96–97 ◦C; 1H-NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 4.61 (d, J = 7.9 Hz, 1H),
4.48 (dt, J = 14.2, 4.2 Hz, 1H), 4.40–4.31 (m, 1H), 4.20 (dt, J = 8.9, 4.4 Hz, 1H), 3.91–3.85 (m, 1H), 3.66
(t, J = 8.5 Hz, 1H), 2.85 (d, J = 15.3 Hz, 1H), 2.55 (dd, J = 16.2, 5.0 Hz, 1H), 2.30 (t, J = 13.6 Hz, 2H),
2.11–2.03 (m, 1H), 1.89 - 1.82 (m, 2H), 1.75–1.51 (m, 10H), 1.48–1.47 (m, 3H), 1.45–1.38 (m, 3H), 1.32–1.25
(m, 3H), 1.20–1.12 (m, 3H), 1.05–0.96 (m, 2H), 0.91–0.87 (m, 6H), 0.76 (s, 3H), 0.72 (s, 3H). 13C-NMR
(151 MHz, CDCl3) δ 142.96, 131.85, 107.28, 101.25, 97.27, 82.74, 81.99, 68.40, 53.86, 50.95, 48.03, 45.26,
44.14, 43.00, 42.39, 39.98, 36.96, 36.78, 36.31, 35.75, 35.32, 34.56, 34.54, 32.84, 31.34, 30.60, 29.05, 25.01,
23.87, 23.58, 22.18, 20.93, 19.39, 18.78, 11.73, 11.17.
(1R,3aS,5aR,5bR,7aR,12aR,12bR,14aR,14bR)-5a,5b,8,8,12a-Pentamethyl-1-(prop-1-en-2-yl)-9-(2-(((3R,6R,8aS,
9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)-oxy)ethyl)-
2,3,4,5,5a,5b,6,7,7a,8,9,12,12a,12b,13,14,14a,14b-octadecahydrocyclopenta[7,8]chryseno[2,3-d][1,2,3]triazole-
3a(1H)-carboxylic acid (8l): 5 (60 mg, 0.183 mmol), (1R,3aS,5aR,5bR,7aR,11aR, 11bR,13aR,13bR)-
5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylic acid
(83 mg, 0.183 mmol), 4-nitrophenyl azide (36.1 mg, 0.220 mmol). Reaction time was 16 h. The product
was purified by flash column chromatography (first DCM, followed by EtOAc/heptane = 3:2) to
afford 8l (68 mg, 47%) as an off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 4.76
(s, 1H), 4.69–4.63 (m, 2H), 4.59–4.51 (m, 1H), 4.28–4.23 (m, 1H), 4.19–4.11 (m, 1H), 3.06–3.00 (m, 1H),
2.91 (d, J = 15.3 Hz, 1H), 2.31–2.23 (m, 2H), 2.12 (d, J = 15.3 Hz, 1H), 2.03–1.96 (m, 2H), 1.86–1.76
(m, 3H), 1.71 (s, 3H), 1.69–1.63 (m, 3H), 1.60–1.50 (m, 8H), 1.48 (s, 5H), 1.45–1.39 (m, 2H), 1.37
(d, J = 2.5 Hz, 1H), 1.32 (d, J = 7.6 Hz, 4H), 1.29–1.22 (m, 9H), 1.18–1.10 (m, 3H), 1.00 (d, J = 4.6 Hz, 6H),
0.90 - 0.87 (m, 6H), 0.78 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 180.60, 150.37, 141.10, 138.35, 110.01,
107.26, 101.71, 97.31, 82.75, 68.55, 56.48, 54.86, 49.47, 49.31, 49.21, 47.00, 45.30, 44.10, 42.61, 40.75, 39.80,
39.09, 38.59, 38.42, 37.18, 35.29, 34.60, 34.56, 33.76, 33.54, 32.82, 32.22, 30.71, 29.94, 29.84, 28.82, 25.65,
23.90, 22.19, 21.57, 19.55, 19.33, 19.09, 18.80, 16.17, 15.80, 14.83.
(3R,6R,8aS,9R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl
4-oxocyclohexane-1-carboxylate (9): dihydroartemisinin (1 gm, 3.52 mmol), dicyclohexyl-methanediimine
(0.726 gm, 3.52 mmol), 4-oxocyclohexane-1-carboxylic acid (0.600 gm, 4.22 mmol),
N,N-dimethylpyridin-4-amine (0.064 gm,0.528 mmol.). Reaction time was 18 h. The product
was purified by flash column chromatography (DCM/MeOH = 99/1) to give 9 (1.2 gm, 84%) as an
off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 5.82 (d, J = 9.8 Hz, 1H), 5.45 (s, 1H), 2.91–2.75
(m, 1H), 2.60 (ddd, J = 9.9, 7.2, 4.6 Hz, 1H), 2.62–2.58 (m, 1H), 2.55–2.45 (m, 1H), 2.39–2.34 (m, 2H),
2.33–2.27 (m, 1H), 2.25–2.20 (m, 1H), 2.14–2.00 (m, 3H), 1.95–1.87 (m, 1H), 1.81–1.75 (m, 2H), 1.67–1.56
(m, 2H), 1.52–1.46 (m, 1H), 1.45–1.41 (m, 3H), 1.39–1.25 (m, 3H), 1.11–1.00 (m, 1H), 0.97 (d, J = 6.0 Hz,
3H), 0.86 (d, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 210.13, 173.04, 104.63, 92.27, 91.67, 80.25,
77.48, 76.84, 51.70, 45.39, 40.70, 39.87, 39.66, 37.41, 36.33, 34.21, 31.94, 28.78, 28.05, 26.06, 24.71, 22.13,
20.34, 12.30.
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl
1-(4-methylbenzyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (11a): 9 (60 mg, 0.147 mmol),
p-tolylmethanamine (18 mg, 0.147 mmol), 4-nitrophenyl azide (28.9 mg, 0.176 mmol). Reaction time
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was 16 h. Flash column chromatography (first DCM, followed by EtOAc/heptane = 3:2) afforded
purified 11a (53 mg, 67%) as an off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 7.14 (d, J = 7.8 Hz,
2H), 7.08 (d, J = 7.8 Hz, 2H), 5.83–5.69 (m, 1H), 5.48–5.29 (m, 3H), 3.20–3.05 (m, 1H), 3.03–2.91 (m, 1H),
2.86–2.76 (m, 1H), 2.68–2.50 (m, 2H), 2.44–2.36 (m, H), 2.33 (s, 3H), 2.29–2.12 (m, 1H), 2.07–1.99 (m,
1H), 1.95–1.85 (m, 2H), 1.79–1.69 (m, 2H), 1.66–1.57 (m, 2H), 1.54–1.45 (m, 1H), 1.42 (d, J = 1.6 Hz, 3H),
1.38–1.25 (m, 3H), 0.96 (d, J = 5.8 Hz, 3H), 0.80 (d, J = 7.1 Hz, 3H). 13C-NMR (151 MHz, CDCl3) δ 173.24,
172.94, 141.10, 141.06, 136.27, 136.21, 132.13, 127.09, 127.02, 122.90, 122.73, 122.40, 122.24, 119.72, 119.63,
118.14, 118.05, 111.69, 111.62, 111.23, 104.76, 104.72, 92.59, 92.53, 91.82, 80.38, 80.22, 51.74, 51.70, 48.99,
48.80, 45.35, 39.53, 39.38, 37.40, 36.38, 34.18, 32.02, 31.90, 26.77, 26.68, 26.03, 25.92, 25.02, 24.80, 24.69,
24.35, 23.84, 22.15, 20.34, 18.23, 18.04, 12.32, 12.22.
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl
1-(3,4,5-trimethoxybenzyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (11b): 9 (60 mg,
0.147 mmol), (3,4,5-trimethoxyphenyl)methanamine (29 mg, 0.147 mmol), 4-nitrophenyl azide
(28.9 mg, 0.176 mmol). Reaction time was 16 h. The product was purified by flash column
chromatography (DCM at first, followed by EtOAc/heptane = 3:2) to afford 11b (55 mg, 61%) as an
off-white solid: mp 80–81 ◦C; 1H-NMR (400 MHz, CDCl3) δ 6.40 (d, J = 6.8 Hz, 2H), 5.82–5.74 (m, 1H),
5.43 (t, J = 4.6 Hz, 1H), 5.39–5.28 (m, 2H), 3.83 (d, J = 1.0 Hz, 3H), 3.81 (d, J = 1.5 Hz, 6H), 3.20–2.94
(m, 2H), 2.88–2.81 (m, 1H), 2.74–2.54 (m, 2H), 2.52–2.42 (m, 1H), 2.42–2.33 (m, 1H), 2.31–2.20 (m, 1H),
2.02–1.86 (m, 2H), 1.79–1.68 (m, 2H), 1.66–1.59 (m, 1H), 1.42 (d, J = 3.5 Hz, 3H), 1.32–1.23 (m, 4H), 0.97
(d, J = 5.8 Hz, 3H), 0.90–0.84 (m, 2H), 0.81 (d, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 173.06,
172.85, 153.77, 142.64, 142.33, 138.12, 131.47, 131.12, 130.33, 130.30, 104.73, 104.66, 104.61, 104.57, 92.30,
91.65, 80.22, 80.20, 60.97, 56.34, 52.31, 52.28, 51.67, 45.37, 45.33, 39.82, 39.47, 37.39, 36.31, 34.18, 31.92,
31.87, 29.81, 26.03, 25.47, 24.99, 24.68, 24.20, 22.09, 20.31, 19.29, 18.87, 12.24, 12.16.
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl
1-(benzo[d][1,3]dioxol-5-ylmethyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (11c): 9
(60 mg, 0.147 mmol), benzo[d][1,3]dioxol-5-ylmethanamine (22.2 mg, 0.147 mmol), 4-nitrophenyl azide
(28.9 mg, 0.176 mmol). Reaction time was 16 h. The product was purified by flash column
chromatography (first DCM, followed by EtOAc/heptane = 3:2) to give 11c (51 mg, 61%) as an
off-white semisolid: 1H-NMR (400 MHz, CDCl3) δ 6.76 (dd, J = 6.9, 1.7 Hz, 1H), 6.68 (dt, J = 3.7,
1.6 Hz, 2H), 5.96 (s, 2H), 5.83–5.73 (m, 1H), 5.43 (d, J = 3.0 Hz, 1H), 5.39–5.25 (m, 2H), 3.18–3.06 (m, 1H),
3.04–2.92 (m, 1H), 2.87–2.78 (m, 1H), 2.69–2.54 (m, 2H), 2.47–2.33 (m, 2H), 2.28–2.19 (m, 1H), 2.06–1.86
(m, 3H), 1.79–1.69 (m, 2H), 1.66–1.58 (m, 1H), 1.51–1.45 (m, 1H), 1.42 (d, J = 1.9 Hz, 3H), 1.34–1.24
(m, 2H), 1.07–0.98 (m, 1H), 0.96 (d, J = 5.9 Hz, 3H), 0.91–0.84 (m, 1H), 0.83–0.78 (m, 3H). 13C-NMR
(101 MHz, CDCl3) δ 173.09, 172.92, 148.40, 147.87, 142.33, 131.34, 128.43, 121.33, 108.54, 108.21, 108.19,
104.59, 104.55, 101.45, 92.29, 91.64, 80.22, 80.19, 51.98, 51.67, 45.38, 45.33, 39.47, 37.38, 37.36, 36.31, 34.18,
31.92, 31.86, 26.04, 25.50, 24.99, 24.67, 24.23, 22.08, 20.31, 19.36, 18.86, 12.15.
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl
1-(2-(1H-indol-3-yl)ethyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (11d): 9 (60 mg,
0.147 mmol), 2-(1H-indol-3-yl)ethan-1-amine (25.5 mg, 0.147 mmol), 4-nitrophenyl azide (28.9 mg,
0.176 mmol). Reaction time was 16 h. The product was purified by flash column chromatography
(first DCM, followed by EtOAc/heptane = 3:2) to afford 11d (39 mg, 46%) as an off-white semisolid:
1H-NMR (400 MHz, CDCl3) δ 8.42 (d, J = 7.1 Hz, 1H), 7.43–7.33 (m, 2H), 7.22–7.16 (m, 1H), 7.11–7.06
(m, 1H), 6.70 (dd, J = 51.1, 2.3 Hz, 1H), 5.73 (dd, J = 9.9, 6.4 Hz, 1H), 5.47 (d, J = 13.4 Hz, 1H), 4.53–4.31
(m, 2H), 3.37–3.24 (m, 2H), 3.06–2.87 (m, 2H), 2.70–2.55 (m, 2H), 2.42–2.32 (m, 1H), 2.03 (ddd, J = 14.5,
7.3, 4.2 Hz, 1H), 1.93–1.85 (m, 3H), 1.82–1.74 (m, 2H), 1.72–1.61 (m, 4H), 1.54–1.41 (m, 1H), 1.41–1.34 (m,
4H), 1.34–1.25 (m, 2H), 0.97 (d, J = 5.6 Hz, 3H), 0.83 (d, J = 7.1 Hz, 3H). 13C-NMR (151 MHz, CDCl3) δ
173.24, 172.94, 141.10, 141.06, 136.27, 136.21, 132.13, 127.09, 127.02, 122.90, 122.73, 122.40, 122.24, 119.72,
119.63, 118.14, 118.05, 111.69, 111.62, 111.23, 104.76, 104.72, 92.59, 92.53, 91.82, 80.38, 80.22, 51.74, 51.70,
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48.99, 48.80, 45.35, 39.53, 39.38, 37.40, 36.38, 34.18, 32.02, 31.90, 26.77, 26.68, 26.03, 25.92, 25.02, 24.80,
24.69, 24.35, 23.84, 22.15, 20.34, 18.23, 18.04, 12.32, 12.22.
4. Conclusions
In conclusion, a series of newly functionalized artemisinin derivatives has been prepared by using
a organocatalytic multicomponent reaction. The starting precursors 5 and 9 were used for triazolization
reactions resulting in the formation of fused and 1,5-disubstituted 1,2,3-triazole derivatives.
All derivatives were screened against HIV wt and three of the molecules exhibited moderate
activity. The β-tetralone derivatives 8b, 8c, and 8e were inhibitory to HIV-1 replication in cell
culture with a limited cytotoxicity. However, no inhibitory activity was observed against HIV-2
and an NNRTI-resistant double RT mutant (K103N; Y181C) HIV-1 strain (RES056), pointing at an
NNRTI-type mode of action for the active derivatives. Further studies on modification of artemisinin
by triazolization reactions are under investigation and will be reported in due time.
Supplementary Materials: Supplementary materials are available online.
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